# Fragile-X Syndrome FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/fragile-x-syndrome

> 2 upcoming FDA catalysts in Fragile-X Syndrome: low dose of mrm-3379 (MIRM) on October 2027 (primary completion); low dose of mrm-3379 (MIRM) on Oct 2027 to Jan 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q4 2025 | [MRM-3379 trial start](https://sec-api.dev/pdufa/mrm-3379) | MIRM | Fragile-X Syndrome | scheduled | "•Expect to initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS) in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000040/mirm-20250806xexx991.htm)) |
| October 2027 | [Low dose of mrm-3379 primary completion](https://sec-api.dev/pdufa/low-dose-of-mrm-3379) | MIRM | Fragile X Syndrome | scheduled | "NCT07209462 (Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07209462)) |
| Oct 2027 to Jan 2028 | [Low dose of mrm-3379 topline data readout](https://sec-api.dev/pdufa/low-dose-of-mrm-3379) | MIRM | Fragile X Syndrome | scheduled | "NCT07209462 (Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07209462)) |

## Drugs

- [MRM-3379](https://sec-api.dev/pdufa/mrm-3379) (MIRM)
- [Low dose of mrm-3379](https://sec-api.dev/pdufa/low-dose-of-mrm-3379) (MIRM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/fragile-x-syndrome.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Fragile-X Syndrome FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/fragile-x-syndrome

```bibtex
@misc{secapidev_indications_fragile_x_syndrome_20261116,
  title        = {Fragile-X Syndrome FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/fragile-x-syndrome}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_fragile_x_syndrome_20261116","title":"Fragile-X Syndrome FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/fragile-x-syndrome","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
